Applications of CRISPR–Cas systems in neuroscience by Heidenreich, Matthias & Zhang, Feng
Applications of CRISPR-Cas systems in neuroscience
Matthias Heidenreich1,2 and Feng Zhang1,2,3
1Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
2McGovern Institute for Brain Research, Department of Brain and Cognitive Sciences, 
Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 
02139, USA
3Stanely Center for Psychiatric Research, Broad Institute of Harvard and MIT, Cambridge, MA 
02142, USA
Abstract
Genome editing tools, and in particular those based on CRISPR-Cas systems, are accelerating the 
pace of biological research and enabling targeted genetic interrogation in virtually any organism 
and cell type. These tools have opened the door to the development of new model systems for 
studying the complexity of the nervous system, including animal and stem cell-derived in vitro 
models. Precise and efficient gene editing using CRISPR-Cas systems has the potential to advance 
both basic and translational neuroscience research.
Our understanding of brain function at the cellular and circuit level has been greatly 
advanced by functional genomics and the availability of a variety of genetic tools to decipher 
neuronal diversity and function and to model human brain disorders in non-mammalian and 
mammalian organisms. Just as chemical DNA mutagens1 and RNA interference (RNAi)2 led 
to huge leaps in the fields of genetics and developmental biology — mainly as a result of 
research in non-mammalian organisms such as flies, worms, and fish3–5 — precise genetic 
modifications introduced by homologous recombination in embryonic stem cells (ESCs)6 
paved the way for studying the mammalian brain and modeling human diseases in mice and 
rats. For example, many neurological disorders, such as Alzheimer’s disease, are associated 
with genetic risk factors that can be introduced and studied in animal models7. In addition, 
novel approaches based on human ESCs and induced pluripotent stem cells (iPSCs) are 
changing the way that we model cellular processes under normal and pathological 
conditions in vitro. For example, human stem cells can be differentiated into neurons or glia 
to genetically dissect the molecular mechanisms of complex brain disorders in vitro8–12. 
Genome editing technologies are allowing researchers to take full advantage of both animal 
and cellular models and to work more easily with non-traditional model organisms for 
neuroscience research.
Genome editing tools based on site-specific DNA nucleases including zinc finger (ZF) 
nucleases (ZFNs)13–15, transcription activator-like effector (TALE) nucleases 
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(TALENs)16–19 and the Cas effector proteins of clustered regularly interspaced short 
palindromic repeat (CRISPR) systems such as Cas920–25 and Cpf126, 27 have been 
developed to facilitate site-specific genomic modifications. In addition, ZFs28, TALEs29, and 
enzymatically inactive versions of Cas9 (also known as dead Cas9 (dCas9))30 can be 
coupled to functionally different enzymatic domains30–35 or fluorophor proteins36 to achieve 
targeted transcriptional control, epigenetic modification, and DNA labeling (FIG. 1).
ZFNs and TALENs recognize specific DNA sequences through protein-DNA interactions, 
whereas the DNA specificity of Cas proteins is RNA guided. To target Cas proteins to 
specific genomic loci, dual- or single-guide RNAs (sgRNAs)24, 25, 27, 37, 38 can be designed 
and generated quickly. Another key advantage of Cas proteins is that multiple sgRNAs can 
be simultaneously used to edit multiple genes, which can be useful for studying genetic 
interactions and modelling multigenic disorders, something that previously required multiple 
cloning and complex protein engineering steps to achieve with ZFNs and TALENs.
The benefits of using CRISPR-Cas systems to study the nervous system are highlighted by 
several successful applications in a variety of animal species and cell types to study synaptic 
and circuit function39–41, neuronal development42–45 and diseases41, 46. Here, we describe 
how genome editing tools, and in particular those based on CRISPR-Cas enzymes, are 
opening new avenues for neuroscience and biomedical research via the generation of new 
model systems, both in vivo and in vitro, and discuss the challenges and possible future 
applications of this technology for understanding the brain.
Overview of genome editing strategies
Site-specific nucleases including ZFNs, TALENs, and Cas proteins enable precise genetic 
modifications by inducing double-strand DNA breaks (DSBs) at target locations in the 
genome. Two highly conserved DNA repair machinery pathways typically restore DSBs that 
would otherwise result in cell death: non-homologous end joining (NHEJ) and homology-
directed recombination (HDR)14, 47–55 (FIG. 1a). The highly error-prone NHEJ pathway 
induces insertions and deletions (indels) of various lengths that can result in frameshift 
mutations and, consequently, gene knockout. By contrast, the HDR pathway directs a precise 
recombination event between a homologous DNA donor template and the damaged DNA 
site, resulting in accurate correction of the DSB. Therefore, HDR-repair can be used to 
introduce specific mutations or transgenes into the genome. Because ZFNs and TALENs 
achieve specific DNA binding via protein domains, individual nucleases have to be 
synthesized for each target site. By contrast, Cas proteins are guided by a specificity-
determining guide RNA sequence (CRISPR RNA (crRNA)) that is associated with a trans-
activating crRNA (tracrRNA) and forms Watson-Crick base pairs with the complementary 
DNA target sequence, resulting in a site-specific DSB 22, 23, 37, 56. A simple two-component 
system (consisting of Cas9 from the bacterium strains Streptococcus pyogenes (SpCas9) or 
Staphylococcus aureus (SaCas9), and a fusion of the tracrRNA:crRNA duplex to a single 
guide RNA (sgRNA))37 has been engineered for expression in eukaryotic cells and can 
achieve DNA cleavage at any genomic locus of interest24, 25, 57. More recently, Cpf1, a 
single-RNA guided nuclease, has also been adapted for genome editing27. Hence, different 
Cas proteins can be targeted to specific DNA sequences simply by changing the short 
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specificity-determining part of the guide RNA, which can be easily achieved in one cloning 
step.
Gene editing across species
Non-human animal models provide an experimental platform to dissect the complexity of 
the brain and study the cellular and molecular underpinnings of brain disorders. 
Neuroscience in particular benefits from exploiting a wide diversity of species including 
worms, flies, fish and mammals as well as non-traditional model systems such as birds and 
amphibians58. Disrupting gene expression is a common approach to study gene function and 
understand loss-of-function disease mutations. For many years, RNAi was the gold standard 
for gene silencing and studying gene function in vitro and in vivo59, 60; however, genome 
editing based on engineered designer nucleases offers several advantages over RNAi 
(TABLE 1). For example, genome editing tools can be modified to allow for more refined 
control gene expression beyond simple gene knockdown, adding to their versatility (FIG. 
1d).
Multiplying the power of simple model organisms
At the molecular level, non-mammalian model systems can provide important information 
about fundamental features of the nervous system as a result of their well-characterized 
genetic and cellular organization and amenability to a variety of genetic tools. For example, 
many evolutionarily conserved genes involved in human neurological disorders such as 
Alzheimer’s or Parkinson’s disease have been extensively studied using flies, worms, and 
fish61–63. For years, studies using these simple model organisms relied mainly on genetic 
screens using chemical mutagenesis and RNAi3–5 or imprecise methods for transposon 
excision and retroviral insertion64–66. More precise genetic modifications have been 
achieved using ZFNs67–69, TALENs70–73, and Cas9 (reviewed in 74). In the case of Cas 
proteins, large numbers of RNA guides can be easily synthesized to study gene function on a 
large scale. By contrast, generating large libraries based on ZFNs and TALENs is 
challenging due to difficulties in designing and synthesizing these proteins with varying 
DNA binding specificities. In a proof-of-concept study a hundred genes were screened with 
Cas9 and novel loci involved in electrical synapse formation in zebrafish were identified43. 
Such in vivo screening approaches in small model organisms offer an accessible platform to 
identify the genes involved in various aspects of nervous system function and dysfunction.
Rapid generation of mammalian models
The development of methods enabling homologous recombination in embryonic stem cells 
(ESCs)6 enabled neuroscientists to study the effects of gene knockouts mainly in mice. This 
approach has been significantly enhanced by genome editing technologies (FIG. 2). Genome 
editing in single-cell embryos has been used to generate mouse75, rat76, and primate 
models77, 78 that can be used to study the role of specific proteins in nervous system 
function. Mouse and rat models thus provide a bridge between our understanding of the 
molecular underpinnings of the nervous system gleaned from studies in non-mammalian 
systems and the complex phenotypes observed in brain disorders. In some cases, however, a 
comprehensive understanding of the human brain will require primate models, which are 
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more similar to the human brain in terms of neuroanatomical, physiological, perceptual, and 
behavioral characteristics.
Transgenic approaches in primates are generally very inefficient. However, successful 
insertion of transgenic alleles in primates, including macaques79, 80 and the common 
marmoset
81
, has been achieved using retroviral and lentiviral approaches in early embryos. 
For example, the viral insertion of a disease-related version of the human huntingtin gene 
(HTT) into the macaque genome recapitulated clinical features of Huntington’s disease80, 
representing an important step forward for genetic disease modelling in non-human 
primates. TALENs have also been successfully used in monkeys to model mutations in 
MECP2, an X-linked Rett-syndrome gene77, and genome engineered primates have been 
generated by precise disruption of single and multiple genes with Cas978. The simplicity of 
the use of Cas proteins relative to ZFNs and TALENs and the ability to modify multiple 
genes simultaneously is a breakthrough that is already catalyzing molecular interrogation of 
neurological and psychiatric dysfunctions in disease-relevant brain circuits using primate 
models78, 82. The ability to examine brain function in genetically modified non-human 
primates has the potential to contribute significantly to our understanding of higher cognitive 
functions and to the development of new therapeutic strategies for diseases that cannot be 
adequately modeled in rodents. Such research, however, raises important bioethical 
questions, and requires careful consideration of the costs and benefits before moving 
forward.
In vivo gene editing in the brain
In vivo gene editing allows the systematic genetic dissection of neuronal circuits and the 
ability to model pathological conditions while bypassing the need to engineer germline 
modified mutant strains. This experimental approach is fast, independent of genetic 
background, animal species, and availability of ESCs, and can be applied to existing disease 
models and transgenic strains as well as aged animals to study age-related neurological 
changes (FIG. 3). In vivo methods based on RNAi have been commonly used to reduce the 
expression of genes in the brain83. In addition, alternative methods based on DNA antisense 
oligonucleotides (ASOs) can be used for gene silencing and have been shown to be 
promising therapeutic molecules for suppressing pathogenic protein aggregates in the 
brain84, 85. However, both strategies do not allow the generation of stable gene knockouts 
and site-specific epigenetic modifications (TABLE 1). In the mouse brain, histone 
modifications and transcriptional control have been achieved using ZFs86 and TALEs28, and 
Cas9 has been used to induce indel mutations in neurons in order to achieve stable gene 
knockouts in living animals39, 41. This demonstrates the capacity for spatial and temporal 
control of gene expression in fully developed circuits and also opens the door to probing 
epigenetic dynamics30–33, 35 in the brain. Epigenetic control is of particular interest as there 
is increasing evidence that epigenetic mechanisms such as histone modifications and DNA 
methylation play a role in learning and memory formation and the pathology of 
neuropsychiatric disorders87. Using Cas proteins, functional domains of DNA methylation 
or demethylation enzymes or histone modifiers can be easily targeted to specific DNA 
sequences to edit the epigenome with high spatial and temporal specificity in vivo (FIG. 1d).
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Delivery to the brain
Viral vectors are a promising mode for delivery of Cas proteins to the brain. Viral vectors 
have defined, tissue-specific or cell type-specific tropism and can be admitted either locally 
to the brain or through the bloodstream to achieve more systematic tissue penetration88. The 
most attractive gene delivery vectors are adeno-associated viruses (AAV), which afford long-
term expression without genomic integration, are relatively safe, and are non-
pathogenic89, 90. AAV vectors, however, have limited transgene capacity, and the large size 
of the commonly used Streptococcus pyogenes Cas9 variant poses a significant challenge for 
AAV-mediated delivery41, 91. AAV-mediated delivery may become even more challenging 
when Cas9 is enlarged by the fusion of additional functional domains. Smaller Cas9 
orthologs, such as those derived from Staphylococcus aureus, are easier to pack57, making 
them an attractive option for in vivo genome editing in the brain.
Other techniques have been also used to deliver Cas9 and RNA guides to the brain, such as 
in utero electroporation39 and polyethylenimine (PEI)-mediated transfection46. In rodents, 
electroporation and PEI-transfection are easy to use, fast, and efficient at delivering large 
plasmid DNA into a high number of neurons. However, two drawbacks of these techniques 
are their low spatial accuracy of transgene expression and the necessity of prenatal 
intervention, which often results in low viability and targeting of mitotic neuronal precursors 
instead of post-mitotic differentiated neurons.
Alternatively, Cas9 protein itself, rather than the DNA or RNA that encodes it, could be 
delivered, an approach that is particularly interesting for protein-based therapeutics. The 
anionic nature of sgRNA allows the integration of Cas9 protein–sgRNA complexes into 
cationic liposomes, a commonly used DNA, RNA, and protein delivery tool. Liposome Cas9 
protein–sgRNA complexes have already been successfully used to achieve genome editing 
in the mouse inner ear92. Therefore, lipid-mediated delivery of Cas9 may also serve as 
powerful tool for genome editing in the brain in the future.
Cell type specific genome editing
In the mammalian brain there are probably several hundred neuronal subtypes, each with 
distinct morphological, biophysical, biochemical and computational functions. Thus, cell 
type specific tools are required to dissect this heterogeneous tissue. Research has shown that 
malfunction of specific cell types in different brain regions contributes to diverse symptoms 
usually connected with neuropsychiatric symptoms, such as hallucinations, depression, or 
repetitive motor behavior93. This highlights the need to pinpoint causal relationships 
between cell types within the context of relevant neuronal networks, genetics, and behavioral 
dysfunction, which will require precise genome editing in specific cellular subtypes. Site-
specific Cre-LoxP recombination elements that enable the control of the spatio-temporal 
expression of Cas9 have been introduced in fish94 and mouse embryos91, 95 and similar 
approaches could achieve precise gene editing in defined cell types in vivo. The vast number 
of established Cre-driver mouse lines96 and inducible Cas9 systems97–99 can, when 
combined with conditional gene targeting strategies, provide enormous combinatorial power 
to decipher the logic of complex neuronal networks and their role in neurological disorders 
in vivo.
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In vivo efficiency and specificity
In postmitotic neurons, Cas9 has been successfully used to introduce single39–41, 46, 91 and 
multiple DSBs41, 46 resulting in NHEJ and efficient formation of indel mutations. For 
example, AAV delivery of Cas9 and sgRNA targeting Mecp2 in the adult mouse brain 
resulted in MeCP2 protein loss of more than 70%, which was sufficient to recapitulate 
phenotypes observed in classic Mecp2 mouse models and patients41. In another study, Cas9-
mediated deletion of common tumour suppressor genes such as Ptch1, Trp53, Pten and Nf1 
in the cerebellum or forebrain efficiently induced the formation of medulloblastoma or 
glioblastoma tumors, respectively46. Despite this success, the validation of Cas-mediated 
gene editing in the brain is still challenging, and sensitive methods are required for 
analyzing Cas efficiency and specificity in targeted brain regions (BOX 1).
Box 1
Practical considerations for validating Cas nuclease efficiency and 
specificity in the mammalian brain
Validating Cas nuclease efficiency and specificity is particularly challenging in the 
mammalian brain because of its complex architecture and cellular diversity. To precisely 
validate nuclease efficiency and specificity, targeted cells first have to be identified and 
sorted out from the heterogeneous cell population in the brain. Recently, an easy and 
efficient method in which fluorescent activated cell sorting (FACS) is used to isolate 
fluorphor-tagged nuclei of targeted cells to purify and analyze genomic DNA and nuclear 
RNA with high resolution and sensitivity, was developed41.
Cas efficiency
Cas nuclease efficiency and specificity can be validated using enzymatic DNA cleavage 
assays (SURVEYOR®)111 or DNA sequencing41, 46, 91. DNA sequencing analysis 
provides a complete picture of indel frequency, types of frame-shift and in-frame 
mutations, length and exact sequence of insertions and deletions, as well as information 
about mono- and bi-allelic modifications when applied to single cells41. In addition, RNA 
levels of the targeted gene can be determined using quantitative PCR (qPCR) or RNA 
sequencing methods. Depending on the targeted exon (that is, whether it is an early or 
late exon), truncated transcripts might be expressed from the target gene and should also 
be considered when qPCR probes are designed. Ideally, effective protein knockdown 
should also be measured using histological, biochemical, or functional (e.g., 
electrophysiology, enzymatic activity assays) readouts.
Cas specificity
Similar to ZFNs and TALENs, Cas proteins can cleave off-target sites in the genome. 
Many software tools predict potential off-target effects and help to choose optimal target 
sequences to reduce off-target activity (a noncomprehensive list of online tools can be 
found in ‘Further information’). On-target specificity can be further improved by using 
double-nicking112, 113 or truncated sgRNA approaches114. In addition, sensitive readout 
methods for identifying genome-wide Cas9 off-target activity have been developed that 
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provide useful tools for evaluating specificity and safety of Cas9 in basic and clinical 
research57, 115, 116
Selected online off-target prediction tools
CRISPR Design (http://crispr.mit.edu/), sgRNA designer (http://www.broadinstitute.org/
rnai/public/analysis-tools/sgrna-design), CHOPCHOP (https://
chopchop.rc.fas.harvard.edu/), Benchling (https://benchling.com/crispr), CasOT (http://
eendb.zfgenetics.org/casot/), E-CRISP (http://www.e-crisp.org/E-CRISP/), ZiFiT (http://
zifit.partners.org/ZiFiT/, DESKGEN (https://www.deskgen.com/landing/#/), COSMID 
(http://omictools.com/cosmid-s9890.html).
Although NHEJ in postmitotic neurons has been demonstrated to be active, it remains 
unclear how efficient HDR is in postmitotic cells. It is commonly believed that HDR 
predominantly occurs in the S and G2 phases of the cell cycle100, 101, and is therefore 
thought to be rare in non-dividing cells such as neurons. Introduction or correction of precise 
genetic mutations via HDR in the brain would validate disease mutations in vivo and open 
the door to therapeutic applications of genome editing in brain disorders. Thus, future work 
should focus on identifying and activating signaling pathways required for triggering HDR 
in differentiated cells. It should also be noted, however, that gene insertion has been 
achieved through NHEJ pathways, which may allow us to insert DNA in neurons and 
glia102.
In contrast to precise gene knockout and insertion, genome editing aimed at transcriptional 
regulation and epigenetic modulation may be less challenging in the brain, as these 
approaches are independent of DNA repair pathways. Achieving epigenetic control in 
neurons can aid in the study of the molecular mechanisms of natural gene silencing in the 
nervous system and to better understand neurological disorders associated with gene 
imprinting, such as Angelman syndrome103.
Gene editing in human iPSCs
Combinatorial approaches based on iPSC technology and genome editing offer another 
approach to model human neurological disorders in vitro. A key advantage of this approach 
is that genetic modifications can be studied in different human genetic backgrounds because 
iPSCs retain all of the individual donor’s genetic information. For complex neurological 
disorders this is particularly important because genetic variants associated with such 
diseases act in concert with many other alleles. Another advantage is that the genetically 
modified cells can be differentiated into virtually any cell type, including those that are not 
easily accessible in patients such as neurons and glia.
iPSC-based disease models have been generated for several neurological disorders including 
Parkinson’s10, 11, Alzheimer’s9, and Huntington’s8 disease and have been proven to closely 
mimic cellular and molecular features of human diseases. Genome editing tools applied to 
these models can be used to examine the genetic link between risk variants and cellular 
pathways involved in multigenic neurological disorders in a high-throughput manner (FIG. 
4). Furthermore, specific signaling pathways involved in the pathogenesis of the disease can 
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be precisely dissected to gain insight into the molecular mechanisms of the disease and to 
identify new drug targets10. Gene editing may be performed either in iPSCs or later in 
differentiated cells97, 99, allowing for the investigation of phenotypes that arise during cell 
differentiation, which may be relevant when studying neurodevelopmental aspects of a 
disease such as in Rett-syndrome104–106. On the other side, inducing or rescuing a 
phenotype in differentiated cells will be useful for validating potential therapeutic 
applications.
Future perspectives
Genome editing technologies allow for the introduction of genetic modifications into 
virtually any cell type and organism. For example, Cas9 has been already used to alter genes 
in species such as killifish107 and salamander108, which are commonly used to study aging 
and tissue regeneration, respectively. It may also open up the possibility of developing 
models in other species of interest to neuroscience research, such as social insects or 
songbirds58, which have been intractable to genetic modification. In addition to generation 
of new model systems, including iPSC-derived in vitro models, genome editing in 
combination with single-cell transcriptomics109 provides a route to understanding cell type 
specific gene function within a heterogeneous tissue, allowing for precise dissection of 
genetic networks in the brain. Furthermore, together with genome-wide association studies, 
in vivo genome editing holds potential for personalized therapeutic applications for brain 
disorders110. To realize these advances, however, several open challenges have to be 
addressed. First, existing methods for delivering Cas proteins and RNA guides to the brain 
must be optimized and new methods developed to achieve sufficient levels of specificity and 
efficiency. Second, new methods for stimulating efficient gene insertion and correction in 
postmitotic cells have to be established. Third, safety and ethical concerns have to be 
carefully addressed. Nevertheless, we believe that novel genome editing technologies based 
on CRISPR-Cas systems, together with powerful readout methods, will help us better 
understand the logic of neuronal circuits and unravel some of the mysteries of complex 
neurological disorders in the near future.
Suggested glossary terms
Functional genomics Studying gene functions and interactions in relationship 
to RNA transcripts and protein products using genome-
wide data, and often involving high-throughput methods.
RNA interference (RNAi) A technique used to knock down the expression of a 
specific gene by introducing a double stranded RNA 
molecule that complements the gene of interest and 
triggers the degradation of the target mRNA.
Homologous recombination (HR)Exchange of homologous DNA strands between similar 
DNA molecules, which naturally occurs during meiosis 
to generate genetic variation. HR is used to direct error-
free repair of DNA double-strand breaks induced by 
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DNA nucleases such as ZFNs, TALENs, and Cas 
proteins.
Embryonic stem cells (ESCs) Totipotent cells derived from embryos that can be 
genetically manipulated in vitro to generate transgenic, 
knockin and knockout mice. ESCs can also be directed 
to differentiate into a variety of cell types in vitro 
including neurons and glial cells.
Induced pluripotent stem cells (iPSCs)Pluripotent cells derived from reprogrammed 
differentiated adult cells with similar properties as ESCs, 
and therefore can be differentiated in principle into all 
cell types of the body.
Epigenetic mechanisms Multilayered cellular processes that modulate gene 
expression and function in response to interoceptive and 
environmental stimuli during development, adult life and 
ageing, including DNA methylation, post-translational 
histone modifications, ATP-dependent nucleosome and 
higher-order chromatin remodelling, non-coding RNA 
deployment and nuclear reorganization.
Liposomes A lipid vesicle artificially formed by sonicating lipids in 
an aqueous solution. Liposomes can be packed with 
negatively charged molecules to deliver them into cells, 
and are therefore promising vehicles for therapeutic 
applications.
Cre-LoxP recombination A site-specific recombination system derived from 
Escherichia coli bacteriophage P1. Two short DNA 
sequences (loxP sites) are engineered to flank the target 
DNA. Activation of the Cre-recombinase enzyme 
catalyses recombination between the loxP sites, leading 
to excision of the intervening sequence.
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Figure 1. Genome editing applications of CRISPR-Cas9
(a) Non-homologous end-joining (NHEJ) and homology-directed repair (HDR) after DNA 
double-strand break (red arrowheads) induced by zinc finger nucleases (ZFNs) or 
transcription activator-like effector nucleases (TALENs) (left) and Cas9 (right). ZFNs and 
TALENs recognize their DNA binding site via protein domains (indicated in blue) that can 
be modularly assembled for each DNA target sequence. Cas9 recognizes its DNA binding 
site via RNA-DNA interactions mediated by the short guide RNA (sgRNA), which can be 
easily designed and cloned. The error-prone NHEJ repair pathway53 can result in 
introduction of indel mutations that can lead to a frame shift, introduction of a premature 
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stop codon and consequently gene knockout. The alternative HDR repair pathway14, 47–53 
can be used to introduce precise genetic modifications if a homologous DNA template is 
present. (b) Two different sgRNAs guide Cas9 to induce DNA cleavage at two different 
genes, resulting in chromosomal rearrangements117, 118. (c) Two proximate sgRNAs guide 
Cas9 to induce DNA cleavage at two different loci of the same gene, introducing large 
deletions119, 120. (d) The nuclease inactivated version of Cas9 (dead Cas9 (dCas9)) can be 
fused to different functional enzymatic domains in order to mediate transcriptional control, 
epigenetic modulation editing, or fluorescent DNA labeling of specific genetic loci30–36.
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Figure 2. Methods for generating genetically modified rodents
Comparison of the timelines of traditional gene targeting using classic homologous 
recombination (HR) in embryonic stem cells (ESCs) or Cas9 in one-cell embryos. (a) There 
are two main time- and cost-intensive phases of the HR approach. The first, is the design and 
cloning the targeting vector, ESC transduction and selection, and generation of chimeras. 
The second is the backcrossing of mice to a desired background and/or crossbreeding in 
order to generate multiple genetically modified animals. (b) By contrast, cloning of sgRNA 
into targeting vector, verification of sgRNA on-target efficiency, Cas9/sgRNA 
microinjection, and founder identification are relatively easy and fast95, 121. Because 
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embryos can be obtained from any mouse strain and multiple genes can be targeted 
simultaneously, no genetic backcrossing and crossbreeding is required.
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Figure 3. In vivo genome editing strategies using viral delivery of Cas9 in the mammalian brain
Cas9 nucleases enable precise in vivo genome editing of specific cell types in the 
mammalian brain on a relatively short time-scale. Cas9 is cloned under the control of cell 
type specific promoters and sgRNA efficiency is validated in vitro before being packaged 
into viral vectors such as adeno-associated viruses (AAV). sgRNA can then be 
stereotactically delivered into the brain of mice that express endogenous Cas9 expression 
(Cas9 mice, (left))91, or together with Cas9 into wildtype mice41 or rats, aged and disease 
models, or reporter lines. In vivo genome editing in the brain is not limited to rodents and 
can be theoretically applied to other mammalian systems including non-human primates 
(right). hSyn: human Synapsin promoter; GFAP: glial fibrillary acidic protein.
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Figure 4. In vitro application of Cas-based genome editing in human induced pluripotent stem 
cells (iPSCs)
(a) Evaluation of disease candidate genes from large-population genome-wide association 
studies (GWAS). Human primary cells such as neurons are not easily available and are 
difficult to expand in culture. By contrast, iPSCs derived from somatic cells (such as 
fibroblasts) of healthy individuals or patients with neurological disorders can be 
differentiated into neurons and cultured in vitro8–12. Disease candidate genes can be 
examined in two ways. Site-specific homologous recombination (HDR) of the candidate 
gene using Cas nucleases can be applied in disease-affected cells (top). If this rescues 
disease phenotypes (as for candidate gene B in the example shown) the validity of the 
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candidate gene is confirmed. Alternatively, candidate genes can be mutated in healthy cells 
(bottom). Where this recapitulates disease pathogenesis in vitro (as in the case of candidate 
gene B) the validity of the candidate gene is confirmed. (b) The contribution of specific 
genetic loci to multigenic disorders such as Alzheimer’s or Parkinson’s disease can be 
systematically evaluated using Cas-mediated single and multiplex genome editing. This may 
enable the dissection of possible synergistic effects (as shown for candidate genes A and B) 
and screening for functional correlations between disease phenotypes and distinct gene 
mutations.
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